The 10-second takeaway
For the quarter ended Dec. 31 (Q4), DepoMed met expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. GAAP loss per share dropped.
Gross margins dropped, operating margins grew, net margins expanded.
DepoMed booked revenue of $26.6 million. The four analysts polled by S&P Capital IQ foresaw net sales of $26.6 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $12.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.07. The four earnings estimates compiled by S&P Capital IQ predicted -$0.11 per share. GAAP EPS were -$0.07 for Q4 against -$0.25 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 91.3%, 360 basis points worse than the prior-year quarter. Operating margin was -14.6%, 9,100 basis points better than the prior-year quarter. Net margin was -13.9%, 10,020 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $28.1 million. On the bottom line, the average EPS estimate is -$0.09.
Next year's average estimate for revenue is $138.9 million. The average EPS estimate is $0.04.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 231 members out of 251 rating the stock outperform, and 20 members rating it underperform. Among 56 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give DepoMed a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DepoMed is buy, with an average price target of $9.33.
- Add DepoMed to My Watchlist.